Stockscreener 앱 받기
16.30
3.16%
0.50
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
How Ozempic Brought a Napster Moment to Big Pharma - The Wall Street Journal
Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of "Hold" by Brokerages - MarketBeat
Hims & Hers Health (HIMS) Is Down 29.2% After Semaglutide Lawsuit And DOJ ReferralHas The Bull Case Changed? - Yahoo Finance
Hims & Hers Unveils New Health Offerings Amid Patent Disputes - timothysykes.com
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know - The Globe and Mail
Hims & Hers Falls Over 50% as Novo Files Obesity Lawsuit - GuruFocus
Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More - Benzinga
Hims & Hers Health (HIMS) Faces Legal and Market Challenges - GuruFocus
HIMS Stock Sees Bullish Options Activity with Earnings on the Ho - GuruFocus
Hims & Hers short interest climbs amid legal risk related to weight loss pill - Seeking Alpha
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows - whbl.com
Exclusive: Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators - Sherwood News
Hims & Hers Shorts Up $1.3 Billion This Year on Legal Risk - Bloomberg.com
Hims & Hers (HIMS) Faces High Short Interest Amid FDA Speculatio - GuruFocus
Most and least shorted mid-to mega-cap healthcare stocks in January - Seeking Alpha
Analysis-US could take action including fines against Hims after brief Wegovy copy launch - WKZO
HIMS Stock Falls -47% With A 10-day Losing Spree On FDA Crackdown - Trefis
Hims & Hers Health (NYSE:HIMS) Hits New 52-Week LowHere's Why - MarketBeat
Hims & Hers Strengthens Integrated Personalized Digital Care Platform - The Globe and Mail
Mixed options sentiment in Hims and Hers Health with shares down 2.18% - Yahoo Finance
Him & Hers Health Stock Forecast 2026–2030 | Future Outlook - Capital.com
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs - Benzinga
Hims & Hers Pulls Wegovy Pill Dupe After FDA Threats — Novo Nordisk Files Patent Lawsuit Anyway - Everyday Health
Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials - Bloomberg.com
Hims & Hers Faces Legal and Regulatory Headwinds, Stock Plummets - StocksToTrade
HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? - Stocktwits
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? - The Globe and Mail
Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
HIMS Selloff Creates De-Risked Entry (NYSE:HIMS) - Seeking Alpha
Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning - AOL.com
Pharmaceutical industry spends more on ads in the US despite stricter FDA guidelines - medwatch.com
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 46% - simplywall.st
Novo’s GLP-1 Patent Suit Against Hims Takes Aim at Compounding - Bloomberg Law News
Hims is in the crosshairs. Is a crackdown coming for compounding? - statnews.com
Deutsche Bank Maintains Hold on HIMS (Hims & Hers) Feb 10, 2026 - Meyka
'Health risk': Novo Nordisk sues Hims & Hers over cheaper version of Ozempic, Wegovy fat loss pills - MSN
Meet The Attys For Novo Nordisk In Hims & Hers GLP-1 Row - Law360
Legal pressures mount for Hims & Hers over GLP-1 sales - The Hill
Novo Nordisk Takes On Hims Over Copycat GLP-1 Pill - Law360
Stocks making big moves yesterday: Shopify, Snowflake, Ryan Specialty, Merchants Bancorp, and Hims & Hers Health - The Globe and Mail
Novo Nordisk Files Patent Lawsuit Against Hims & Hers Over Compounded Semaglutide Products - Law Commentary
Hims & Hers Health (NYSE:HIMS) Shares Down 6% Following Analyst Downgrade - MarketBeat
Fight over GLP-1 alternatives escalates as Novo Nordisk sues Hims & Hers - Axios
Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’ - The Hill
Decoding Hims & Hers Health's Options Activity: What's the Big Picture? - Benzinga
Palmetto Grain Brokerage - Palmetto Grain Brokerage
As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock? - Barchart.com
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS) - FinancialContent
Deutsche Bank Cuts Price Target on Hims & Hers Health to $31 From $42, Keeps Hold Rating - marketscreener.com
Hims & Hers Health Stock (HIMS) Opinions on Novo Nordisk Lawsuit - Quiver Quantitative
Novo Nordisk, maker of Ozempic, sues over weight loss drug copycats - NewsNation
Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans - Yahoo Finance
Hims & Hers Health, Inc. $HIMS Shares Purchased by Candriam S.C.A. - MarketBeat
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny - TechStock²
Hims And Hers Retreats On GLP1 Pills As Legal And Regulatory Risks Grow - Yahoo Finance
1.19%
0.83%
자본화:
|
볼륨(24시간):